

Supplemental Table 1: Clinical characteristics of patient cohort

Characteristics	n (%) or mean (range)
All patients	171
Receptor status	
ER+/PR+/Her2±	135 (79%)
ER-/PR-/Her2+	8 (5%)
ER-/PR-/Her2-	28 (16%)
Tumor subtype	
Invasive ductal carcinoma	136 (80%)
Lobular carcinoma	23 (13%)
Mucinous carcinoma	3 (2%)
Mixed	9 (5%)
Patients lost to follow-up	10
With recurrent cancer	1
Patients included in prospective analyses	161
Alive at last follow-up	125 (78%)*
Death from cancer during study period	25 (15%)
Death from other causes	11 (7%)
Time to relapse, mo	28 (2-54)
Follow-up time, mo	
All patients, median	52 (2-92)
Patients still alive	54 (2-92)
Patients dead	31 (3-78)

* percentage of patients in prospective analyses, excluding those lost to follow-up